LINAGLIPTIN; METFORMIN HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for linagliptin; metformin hydrochloride and what is the scope of freedom to operate?
Linagliptin; metformin hydrochloride
is the generic ingredient in three branded drugs marketed by Boehringer Ingelheim, Sunshine, and Zydus Pharms, and is included in four NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Linagliptin; metformin hydrochloride has three hundred and eighty-nine patent family members in forty-five countries.
One supplier is listed for this compound. There are two tentative approvals for this compound.
Summary for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
International Patents: | 389 |
US Patents: | 11 |
Tradenames: | 3 |
Applicants: | 3 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 61 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LINAGLIPTIN; METFORMIN HYDROCHLORIDE |
DailyMed Link: | LINAGLIPTIN; METFORMIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medanta, The Medicity, India | N/A |
Dong Wha Pharmaceutical Co. Ltd. | Phase 1 |
The First Affiliated Hospital with Nanjing Medical University | N/A |
See all LINAGLIPTIN; METFORMIN HYDROCHLORIDE clinical trials
Generic filers with tentative approvals for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 2.5MG; 1G | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 2.5MG; 850MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 2.5MG; 500MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Drug Class | Biguanide Dipeptidyl Peptidase 4 Inhibitor |
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Paragraph IV (Patent) Challenges for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
JENTADUETO XR | Extended-release Tablets | linagliptin; metformin hydrochloride | 2.5 mg/1000 mg 5 mg/1000 mg | 208026 | 1 | 2018-03-28 |
JENTADUETO | Tablets | linagliptin; metformin hydrochloride | 2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg | 201281 | 8 | 2015-05-04 |
US Patents and Regulatory Information for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Expired US Patents for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
EU/EMA Drug Approvals for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim International GmbH | Jentadueto | linagliptin, metformin hydrochloride | EMEA/H/C/002279 Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. |
Authorised | no | no | no | 2012-07-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Eurasian Patent Organization | 202091999 | ПРИМЕНЕНИЕ ИНГИБИТОРОВ DPP IV | ⤷ Sign Up |
Poland | 403104 | Sposób otrzymywania kompozycji farmaceutycznej zawierajacej pochodne 8-[3-aminopiperydyn-1-ylo]ksantyny (Method for preparing a pharmaceutical composition comprising derivatives of 8 - [3-Amino-piperidin-1-yl]-xanthine) | ⤷ Sign Up |
Chile | 2012002527 | Medio de aislamiento y conservación para islotes de langerhans o células beta, donde el medio que refuerza la vitalidad y la capacidad de secreción de las células contiene entre 1 nmol/l y 1 µmol/l de un inhibidor de dipeptidil peptidasa iv (dpp iv o cd26); procedimiento para reforzar la vitalidad y capacidad de secreción de islotes de langerhans o células beta durante la fase de aislamiento y transplante. | ⤷ Sign Up |
Mexico | 2022001797 | TRATAMIENTO DE LA DIABETES EN PACIENTES CON CONTROL GLUCEMICO INSUFICIENTE A PESAR DE LA TERAPIA CON UN FARMACO ORAL O NO ORAL ANTIDIABETICO. (TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG.) | ⤷ Sign Up |
South Korea | 20160042174 | 추가의 항당뇨병제와 병용된 DPP-IV 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법 (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION) | ⤷ Sign Up |
South Korea | 20200128209 | DPP-IV 억제제의 용도 (- Use of DPP-IV inhibitors) | ⤷ Sign Up |
Eurasian Patent Organization | 036618 | СПОСОБ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ ВЫРАЖЕННОГО ДИАБЕТА 2 ТИПА С ПОМОЩЬЮ ИНГИБИТОРА DPP IV (METHOD OF THERAPEUTIC TREATMENT OF MANIFEST TYPE 2 DIABETES USING DPP IV INHIBITOR) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1532149 | 2011C/038 | Belgium | ⤷ Sign Up | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2--YLMETHYL)-3,7-DIHYDROPURIN-2,6-DIONE SES ENANTIOMERES OU L'UN DES SES SELS, EN PARTICULIER LA LINAGLIPTINE; AUTHORISATION NUMBER AND DATE: EU/1/11/707/001 20110830 |
1532149 | CA 2013 00001 | Denmark | ⤷ Sign Up | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720 |
1532149 | C01532149/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012 |
1532149 | PA2011013,C1532149 | Lithuania | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082 |
1084705 | C01084705/04 | Switzerland | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012 |
1532149 | C300504 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN ZOUT; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824 |
1532149 | CR 2011 00030 | Denmark | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTIN OG SALTE DERAF; NAT. REG. NO/DATE: EU/1/11/707/001-011 20110830; FIRST REG. NO/DATE: EU EU/1/11/707/001-0011 20110830 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.